In this study, we used salubrinal (an eIF2α phosphatase inhibitor) to demonstrate that activation of the eIF2α–ATF4 pathway itself may enhance the cisplatin resistance of human gastric cancer cells. Here, EIF2A is linked to gastric cancer.